




NEW WAVES IN THE BIOTECH INDUSTRY

- Entrepreneurship
- Stem Cells/ IP/ Regulatory
- Diagnostics/ Drug Delivery/ Digital Health



The 17th Annual Conference
October 4, 2014, 9:00 am ~ 5:00 pm
Crowne Plaza, Foster City, California

Your Complete Source for API Services

ScinoPharm delivers high-value solutions to customers with speed and flexibility through a full range of services from active pharmaceutical ingredient (API) development to commercialization. With research and manufacturing facilities in both Taiwan and China, ScinoPharm provides rich product portfolio, helping clients deliver high-quality products with efficiency and speed time to market. We also provide a one-stop-shopping service by expanding into the field of oncological injectable formulation.



Come and Join Us

In line with our rapid expansion, we are constantly looking for highly motivated and ambitious candidates to join our growing team. We invite interested candidates to send your resume directly to: resume@scinopharm.com

- New Drug Development - Bioassay Scientist
- New Drug Development - Synthetic/Medicinal Scientist
- Analytical Support Head
- Formulation Development - Pharmacokinetics Scientist



台灣神隆股份有限公司
ScinoPharm Taiwan, Ltd.

<http://www.scinopharm.com>



www.cbaf.org
Email: info@cbaf.org
October 2014

Editor-in-Chief: Cindy Liu

EDITORIAL

Senior Editor:
Caesar Ho

Layout Editor:
Hui Fang Li

Advertising Editor:
Jing Folsom

ART AND PHOTOGRAPHY

Cover/Layout Designer:
Cindy Liu

Photographers:
Cindy Liu, Mark Chen

Logo Designer:
Candy Tang

Published for annual
conference, education and
communication

Copyright © 2014 CBA
All right reserved

Printer: E&T Printing

Contents

- 2 President's Message
- 3 Conference Chair's Message
- 4 Conference Agenda
- 5 Conference Program
 - Includes success stories from several biotech startups and covers topics from stem cells, drug delivery, diagnostics, mobile health, intellectual property and regulatory hurdles.
 - Session I: Entrepreneurship
 - Lunch Session
Ho Family Scholarship Award
 - Session II: Stems Cells/Regulatory/Drug Delivery
 - Session III: Diagnostics/Digital Health
- 18 Sponsors
 - CBA appreciates the generous support of our sponsors.
- 19 Organization and Events
 - State CBA organization and mission. Introduce the 2014 board, advisors and events.
- 20 Big Data Workshop
- 21 Job Search and Interview Workshop
- 22 Investing Across Borders
- 23 Annual Summer Picnic and Monthly Newsletters
- 24 Bioscience Community
 - CBA provides a platform for scientific professionals to network and build a community for learning, sharing and growing together.
- 25 CBA History
 - Share a story by one of the founders. Learn their names and acknowledge them for their diligent dedication and tireless efforts to support the organization.
- 26 College Connection
 - Lists useful online resources for high school and college students.
- 36 Conference Exhibitors

President's Message

Confucius once said, “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.”



Michelle Chen, Ph.D.
2014 President

As a bi-lingual non-profit organization, the Chinese Bioscience Association (CBA) focuses on people. We are here to promote education, networking and community building for life science professionals. Since its foundation in the late 90s, CBA has played a key role bridging the scientific, business and cultural gaps among US, Taiwan, Mainland China and Hong Kong. We have hundreds of active members in the San Francisco Bay Area and a network exceeding one thousand life science professionals across continents. All share a passion for bioscience and its role in improving human health.

It is my great honor to serve as this year's President. Our key goal in 2014 is to leverage the great partnerships we have in the Bay Area in order to address the common interests of our diverse communities. For example, we hosted the “Big Data Challenges Workshop” with BayHelix, inviting experts from IBM, Stanford and Thermo Fisher to discuss big data handling issues. The “Job Search and Interview Workshop” co-hosted with CABS drew over one hundred participants who wanted to learn about interview techniques. CBA also initiated the “Investing Across Borders Panel” with BayBio which attracted top VCs such as Takeda Ventures, Morningside, WuXi and De Cheng Capital. Furthermore, our popular annual summer picnic in Mitchell Park enjoyed an all-time record turnout. We even had a number of park visitors stopping by to ask us about CBA and what made us special.

Finally I want to express my thanks to all CBA board members, advisors, sponsors and volunteers for their generous support and commitment. Together we are making a difference and investing in the future by “teaching the people”.

A handwritten signature in black ink, appearing to read 'Michelle Chen' in a cursive style.

Michelle Chen

Conference Chair's Message

It is with great pleasure that I welcome you to the 2014 CBA Annual Conference. The theme for this year's conference is "New Waves in the Biotech Industry". We will explore many of the different cutting-edge research, innovations and technologies sweeping across our industry.

There are four sessions in the conference. In Session I, Dr. Frank McCormick will recall the successes and failures in developing various cancer therapies at ONYX Pharmaceuticals. Mr. Stephen Isaacs will share the story of the many challenges that he has faced with Aduro BioTech. Next, Dr. Chandler Robinson will discuss the origin of his biotech company, Tactic Pharma, starting from his days as an undergraduate researcher. Dr. Joan Lau will give us a venture capitalist's perspective on the current state of affairs.

For the Lunch Session, we will present the inaugural Ho Family Scholarship Awards. Dr. Jo Shen will then speak about her personal commitment to making ScinoPharm a world class pharmaceutical company in Asia.

In Session II, Dr. Joseph Wu will discuss the latest discoveries in stem cell research to combat cardiovascular diseases. In the following segment, Mr. Scott Cunningham will provide us with a regulatory perspective on stem cell therapy. Dr. Maninder Hora will give us an update on Nektar Therapeutics and its pipeline. Mr. Zander Strange will then discuss Zosano Pharma's innovative trans-dermal drug delivery technology.

In Session III, Dr. Christopher Bunker will introduce Advanced Cell Diagnostic's technologies that enable more effective cancer treatments with targeted therapeutics. Dr. Gabriel Chao will discuss his experience in developing "tele-medicine" and "mobile health" amid the growing use of mobile devices in health care. Finally, Dr. Yiyou Chen will share with us Percans Oncology's unique personalized cancer diagnostic methodology.

It is going to be a very informative and exciting conference. You will gain new insights into some of the most interesting and innovative ideas that drive the companies featured this year. The sessions promise to provide a good platform for lively discussion, inspiration and new idea generation. Thank you for your continued support. Enjoy the conference.



Patty Kiang



Patty Kiang, Ph.D.
2014 Conference Chair

CONFERENCE AGENDA

- 9:00 – 9:30 am Registration, Networking & Exhibitions
- 9:30 – 9:35 am Welcome and Opening Remarks by Dr. Michelle Chen, President
9:35 – 9:40 am Conference Introduction by Dr. Patty Kiang, Conference Chair
- Session I**
9:40 – 10:20 am **Entrepreneurship** (Moderator: Dr. Michelle Chen)
Targeted Cancer Therapy: Successes and Failures at ONYX Pharmaceuticals
(Keynote Speech)
Dr. Frank McCormick, Professor, UCSF, Founder of Onyx
- 10:20 – 10:50 am **The Three Certainties: Death, Taxes and Change**
Mr. Stephen Isaacs, Chairman and CEO, Aduro BioTech
- 10:50 – 11:20 am **From Undergraduate Researcher to CEO: The Tactic Pharma Story**
Dr. Chandler Robinson, CEO, Tactic Pharma
- 11:20 – 11:50 am **Venture Development and Venture Creation - A New Take on "East Meets West"**
Dr. Joan Lau, Founder and Managing Partner of Militia Hill Ventures
- 11:50 – 12:20 pm Networking & Exhibitions
- Lunch Session** (Moderator: Dr. Patty Kiang)
12:20 – 12:30 pm **Ho Family Scholarship Award** (Mr. Caesar Ho)
- 12:30 – 1:00 pm **From San Francisco to Taiwan & China - A Journey of Commitment**
Dr. Jo Shen, Co-Founder & former CEO, ScinoPharm
- Session II**
1:00 – 1:30 pm **Stem Cells/Regulatory/Drug Delivery** (Moderator: Dr. Lin Sun-Hoffman)
iPSCs for Cardiac Drug Discovery and Disease Mechanism
Dr. Joseph Wu, Professor, Standard University, Founder of Stem Cell Theranostics
- 1:30 – 2:00 pm **Stem Cell Therapy: A Regulatory Perspective**
Mr. Scott Cunningham, Partner, Covington & Burling, LLP
- 2:00 – 2:30 pm **Nektar's Pipeline and Technologies**
Dr. Maninder Hora, VP Pharm Dev. & Manufacturing Operations, Nektar Therapeutics
- 2:30 – 3:00 pm **Better Therapeutics Through Innovative Delivery**
Mr. Zander Strange, VP Strategy and Corp. Dev., Zosano Pharma
- 3:00 – 3:30 pm Networking & Exhibitions
- Session III**
3:30 – 4:00 pm **Diagnostics/Digital Health** (Moderator: Dr. Sydney Chen)
Advanced Cell Diagnostics, Inc. - Developing Breakthrough Technologies for Precision Molecular Diagnostics to Enable more Effective Cancer Treatment with Targeted Therapeutics
Dr. Christopher Bunker, VP Business Dev., Advanced Cell Diagnostics
- 4:00 – 4:30 pm **Mobile Health: Rising Tide in Healthcare Industry**
Dr. Gabriel Chao, BD Director, iXensor
- 4:30 – 5:00 pm **The Percans Story**
Dr. Yiyou Chen, CEO, Percans Oncology
- 5:00 pm **Closing Remarks** by Dr. Patty Kiang, Conference Chair

Targeted Cancer Therapy: successes and failures at ONYX Pharmaceuticals

The technical and strategic challenges in anticancer drug development; the story of the successes and failures at ONYX in last twenty years.

Onyx was founded in 1992 to develop cancer therapies based on oncogenes and tumor suppressors. We believed that targeting the mutations that cause cancer would be the most effective strategy. Our first target was Ras. We partnered this Program with Bayer, in a 50:50 partnership. This led to development of sorafenib and, controversially, to fluoro-sorafenib. These drugs have been approved for treatment of renal cell cancer, hepatocellular carcinoma, thyroid cancer and colorectal cancer. However, they failed to produce clinical benefit in cancers in which Ras oncogenes are the major driver. It took more than 20 years to understand why they failed in these indications. Another partnership, this time with Parke-Davis, led to the first successful Cdk4 inhibitor. This compound, now known as palbociclib, recently received FDA Breakthrough Therapy designation for treatment of breast cancer. During this period, I invented ways of treating cancer based on loss of function of p53 or Rb, two major tumor suppressors. These oncolytic viruses did not get developed fully in the US and so far have failed to make a significant clinical impact, for reasons I will discuss. However, based on the early success of sorafenib, Onyx was able to acquire Proteolix and to develop carfilzomib, which was later approved for treating multiple myeloma. The technical and strategic reasons for the successes and failures at ONYX will be discussed.



Dr. Frank McCormick

Professor of UCSF
Founder of Onyx
Pharmaceuticals

Speaker Profile

Frank McCormick, PhD, FRS, is Professor Emeritus of the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick's group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.

Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

The biotech business is like a roller coaster with extreme highs and lows.



Mr. Stephen Isaacs

President and CEO,
Aduro BioTech

The Three Certainties: Death, Taxes and Change

The biotech business is like a roller coaster with extreme highs and lows. The only certainty one can grasp is change, and the only comfort one can derive comes from learning to accept the uncertainty. The companion of uncertainty is change, and change must be embraced, not resisted. The lessons have been lived by many, and I'll share my own wild ride over the past 35 years and how accepting change has led to fun, prosperity and a great way to spend my day (or at least most of them).

Speaker Profile

Stephen T. Isaacs is Chairman, President and CEO of Aduro BioTech. Prior to Aduro, Mr. Isaacs was founder (1991), President and CEO of Cerus Corporation (NASDAQ: CERS), a biomedical products company commercializing the Intercept Blood Systems. During his tenure at Cerus, Mr. Isaacs grew the company from three to over two hundred and fifty employees. He raised over \$650M, negotiated a \$200M partnership with Baxter International, took Cerus public and developed two marketed products. In 2002, while still at Cerus, Mr. Isaacs initiated the current Aduro BioTech immunotherapy program. The immunotherapy technology is based on attenuated strains of *Listeria monocytogenes*, and Mr. Isaacs was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of *Listeria*.

Prior to Cerus, Mr. Isaacs was the CEO of a number of small biotech companies where he negotiated contracts and partnerships with Cetus Corporation, Chiron Corporation, Eastman Kodak, Hoffmann-La Roche and Applied Biosystems. He is an international expert in psoralen photochemistry, and from 1978 to 1986 held a non-teaching faculty position in the Department of Chemistry at UC Berkeley. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents. He holds a BA degree in Biochemistry from UC Berkeley, and had graduate training in organic chemistry in the PhD program in the Department of Chemistry at Berkeley. He is also deeply involved in volunteer work in Kasigau, Kenya through his family non-profit organization, ABE Club, where his family has worked for the past 8 years.

From Undergraduate Researcher to CEO: The Tactic Pharma Story

An inspiring story of a CEO's career path whose undergraduate research led to the finding of the 1st generation version of Tactic Pharma's ATN-224 compound.

In this talk I will share my experience starting a biotechnology company. I will discuss the origins of the company, how the funding came in to place, the science behind the lead drug and how we successfully repositioned it from one indication to a different one, and ultimately how we ended up doing an EU licensing deal followed by an asset sale for rest of the world rights.

The background story is that I researched a drug while an undergraduate, published the results in the journal Science, acquired the drug a few years later with a group in Chicago, applied for and received from the FDA orphan drug designation for the drug, sold it to a company in Sweden, and now it is a Phase III clinical trial away from approval for use in Wilson's Disease.



**Dr. Chandler
Robinson**

**Co-Founder and CEO,
Tactic
Pharmaceuticals**

Speaker Profile

Dr. Robinson is Co-Founder and CEO of Tactic Pharmaceuticals. Prior, he worked at Onyx Pharmaceuticals, Bear Stearns, co-managed a healthcare clinic, and founded an undergraduate research focused non-profit now in its 10th year. His undergraduate research was published in Science, was on the drug Tactic owned but recently sold, and it will be starting Phase III trials shortly.

Dr. Robinson graduated summa cum laude from Northwestern University, earned a master's degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright, an MBA from Cambridge University on a Gates Scholarship, and an MD from Stanford University.

Venture Development and Venture Creation - A new take on "East meets West"

These select portfolio companies and teams are able to access an abundance of resources for success.

Militia Hill Ventures is a venture development and venture creation firm focused on life sciences companies that are developing therapeutics, diagnostics, and devices. We seek superb life sciences innovations worldwide, and our team of experienced entrepreneurs and executives provide operational expertise for our portfolio companies, leveraging the resources of the Philadelphia Collaborative.

These select portfolio companies and teams are able to access an abundance of resources, including preferred access to the expertise, capital, relationships and infrastructure necessary for success. Though we are focused in the Philadelphia area, our reach extends beyond East Coast borders -- both to the West Coast and internationally.

A discussion on the Philadelphia Collaborative, the partnerships, and environment will be discussed, as well as opportunities for those outside of Pennsylvania.

Speaker Profile



Dr. Joan Lau

Managing Partner for Militia Hill Ventures and COO of Immunome Inc.

Joan is Managing Partner for Militia Hill Ventures and COO of Immunome Inc., a cancer immunotherapy company. Dr. Lau has served in executive roles with several venture-backed biotechnology companies including as CEO and President with clinical stage Azelon Pharmaceuticals, Inc. and as CEO and President with Locus Pharmaceuticals, Inc., a computational chemistry discovery company. Prior to Locus, Dr. Lau worked at Merck & Co, in leadership roles within R&D and business development.

Dr. Lau has provided counsel or served in interim leadership roles with several startup life sciences companies, either as a consultant or in her role as Executive-in-Residence for BioAdvance, a funder of life sciences companies in southeastern Pennsylvania. She has served as consultant with venture capital firms investing in healthcare companies, serves on the advisory board for the Temple Masters in Biotechnology program, and is the Associate Course Director for the Vagelos Program in Life Sciences Management. Students in the Vagelos LSM Program receive two degrees from the University of Pennsylvania's School of Arts and Sciences and the Wharton School. Dr. Lau has served on the Board of Directors for Locus, Azelon, and RiboNova Inc. Non-profit service has included Board positions with the Human Rights Campaign (Washington DC) and the Alliance for Women Entrepreneurs (Philadelphia PA).

Dr. Lau earned an MBA from the Wharton School of Business at the University of Pennsylvania. She also holds a PhD in Neuroscience from the University of Cincinnati College of Medicine and a BS in Bioengineering from the University of Pennsylvania.

HO FAMILY SCHOLARSHIP

About Scholarship

The Ho Family Scholarship is established in memory of Ellen & Tony C. Ho. It is also intended to continue the family's tradition of supporting educational endeavors. The family had founded the Chi Yong School in Guangzhou, China and Saigon, Vietnam in the past.

The Scholarship will consist of award(s) of \$500 each in 2014.

Caesar Ho, the elder son of Mr. and Mrs. Ho, will serve as Sponsor on the CBA Board.

Yvonne Ho & Erika Ho, granddaughters, will serve as alternate Sponsors.



Ellen Ho, a nurse practitioner, worked at Tung Wah Hospital in Hong Kong for over 3 decades. She held the position of Head Nurse in the maternity ward before retiring. Tony C. Ho, a chemist by training, worked at Taiwan Sugar in Ping Dong and at San Miguel Brewery in Hong Kong. He joined Merck Sharp & Dohme in 1960, and worked as Plant Manager in Bangkok, Thailand for over 20 years, followed by 10 years at Merck & Co. headquarters in Rahway, New Jersey.

Audrey Cheng 2014 Award Winner

Gunn High School, Palo Alto, 11th Grade

Weighted GPA: 4.3

AP Chemistry test score: 5

SAT 2- Biology: 800

SAT 2- Chemistry: 800

Founder, President: American Chemistry Society Chemistry Club

Founder, Captain: Science Bowl Team

Vice President: Science Olympiad Club

Intended College Major: Biochemistry



Scholarship Committee

The following CBA members are responsible for the evaluation and administration of the scholarship: Hui-fang Li, Jing Folsom, Mark Chen and Patrick Yang.

While building and running ScinoPharm in Asia, with families all in the US, balancing business life and personal life was definitely a challenge. The speaker hopes to share her experiences at the conference.



Dr. Jo Shen

Co-Founder and Board Member, ScinoPharm

From San Francisco to Taiwan & China - A Journey of Commitment

Globalization of drug development and market expansion brought enormous aspirations for scientists, technologists and business people in the West to explore opportunities in Asia. In 1997, a group of senior executives from Syntex, built a world-class API company in Taiwan meeting International GMP standards and specializes in high potency cytotoxic APIs for injectable oncology drugs as well as peptides, currently serving >300 customers in >60 countries. In 2002, ScinoPharm Taiwan began to provide Custom Research and Manufacturing Services (CRAMs) for new drug development companies. To date, 5 NCEs have been commercialized with ScinoPharm being their only API source.

ScinoPharm has since expanded its capacity with a second GMP facility which is in Changshu, Jiangsu, China in 2013. It is currently building a cytotoxic injectable plant in Taiwan to provide one-stop-shop to its existing global customers, as part of “Double A” strategy (API plus ANDA).

Speaker Profile

Dr. Jo Shen is an international pharmaceutical executive with more than 35 years of experience in the industry. She just retired from ScinoPharm which she co-founded in 1997 and served as CEO and President for 17 years. She remains on the Board as a Director. ScinoPharm is a leading process R&D and API manufacturing service provider in Taiwan and China for the global pharmaceutical industry.

Prior to ScinoPharm, Dr. Shen was Corporate VP of Pharmaceutical Operations and Technology for Syntex, where she served for 14 years and was responsible for worldwide pharmaceutical manufacturing, operations, and technology transfer. Before that, she worked at Monsanto for 8 years in various technical and management positions in the synthetic fibers and semiconductor materials divisions.

Dr. Shen is a former board member of the US Pharmaceutical Manufacturer Association (PhRMA), where she chaired the Production Group. She currently serves on a number of boards including the Development Center for Biotechnology, Taiwan Bio-Industry Organization, and Taiwan Pharmaceutical Manufacturing Association (TPMA) where she chairs the API Committee leading the efforts to promote cross-strait cooperation in the API industry.

Dr. Shen holds a Ph.D. in Chemistry from Lehigh University, M.S. in Chemistry from University of Iowa and B.S. of Chemical Engineering from National Taiwan University. Dr. Shen is the recipient of the “Women in Industry” award from the YWCA in California.

Patient-specific and disease-specific iPSC-CMs may be an ideal platform for elucidating disease modeling, drug screening, and cell therapy.

iPSCs for Cardiac Drug Discovery and Disease Mechanism

Heart disease is the most significant cause of morbidity and mortality in the industrialized world, accounting for nearly 33% of all deaths in 2008 within the United States alone. While the use of human induced pluripotent stem cell (iPSCs) in regenerative medicine is a long-term goal, a growing body of studies has shown promising results in the fields of drug discovery, development, and toxicity screening. Specifically, recent technological advancement has enabled the generation of patient-specific and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. These iPSC-CMs carry all the genetic information from the individuals from whom they are derived and hence may be an ideal platform for elucidating disease modeling, drug screening, and cell therapy. Here I will discuss recent advances in this technology in the cardiovascular field.

Speaker Profile

Joseph C. Wu, MD, PhD, is Director of the Stanford Cardiovascular Institute and Professor in the Department of Medicine (Cardiology) and Department of Radiology at the Stanford School of Medicine. Dr. Wu received his M.D. from Yale University School of Medicine. He completed his cardiology fellowship training followed by a PhD in Molecular Pharmacology at UCLA.



Dr. Joseph Wu

Professor and Director
of the Stanford
Cardiovascular Institute

Dr. Wu has received numerous prestigious awards, including the Burroughs Wellcome Foundation Career Award for Medical Scientists (2007), the NIH Director's New Innovator Award (2008), the Baxter Foundation Faculty Award (2008), the NIH Roadmap Transformative Award (2009), the AHA National Innovative Research Award (2009), the Presidential Early Career Award for Scientists and Engineers given by President Obama (2010), and the AHA Established Investigator Award (2013). Dr. Wu is a member of the Association of University Cardiologist (AUC) and American Society of Clinical Investigation (ASCI). Dr. Wu serves on the Editorial Board of *Journal Clinical Investigation*, *Circulation Research*, *Circulation Cardio Imaging*, *JACC Cardio Imaging*, *Human Gene Therapy*, *Molecular Therapy*, *Journal of Nuclear Cardiology*, and *Stem Cell Research*.

Dr. Wu has published >200 manuscripts. His lab uses a combination of genomics, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes. The lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are for (i) understanding cardiovascular disease mechanism, (ii) accelerate drug discovery and screening, and (iii) develop personalized medicine platforms.

Advanced Stem Cell Therapy: A Regulatory Perspective

Stem cell and other cell and tissue based therapies are benefiting from significant innovation. Can regulatory authorities keep up? This talk will focus on regulatory challenges for cellular and tissue based therapies in the United States and China.



Mr. Scott Cunningham

Partner, Covington &
Burling, LLP

Speaker Profile

Scott Cunningham is a partner in the Food and Drug practice group at Covington & Burling LLP. His practice spans the full range of pharmaceutical, biotechnology, medical device, and stem cell product regulation, from clinical development to post-marketing issues. In addition to providing strategic advice to companies dealing with FDA and other regulatory agencies, Mr. Cunningham has litigated cases against FDA and is actively engaged in life sciences transactional and legislative matters. After spending 12 years in Covington's Washington, DC office, Scott is now resident in the firm's San Francisco office.

Nektar's technologies include polymer conjugation technology, releasable linker technology, and pulmonary drug delivery technology.



Dr. Maninder Hora

**SVP of
Pharmaceutical
Development and
Manufacturing
Operations,
Nektar Therapeutics**

Nektar's Pipeline and Technologies

Nektar Therapeutics has one of the strongest pipelines of the biopharmaceutical industry for its size with several products in NDA/BLA or late stage of clinical development. Our partners have successfully employed our polymer conjugation technology to commercialize seven products thus far. Previously applied to proteins only, we have now successfully applied our technology to create NCEs from small molecular drugs. Through polymer conjugation, we can exclude or slow down brain entry of pharmacophores thus creating molecules with very desirable properties for pain management. In the area of oncology, we are leveraging our releasable linker technology to provide prolonged half-life and tumor tissue accumulation of the drug in question. We have also used our technology to create next generation of polymer conjugated proteins with advanced properties. Finally, we have two molecules based on our pulmonary drug delivery technology in phase 3 evaluation. A brief discussion of these points will be provided in the presentation.

Speaker Profile

Maninder Hora, Ph.D., has served as Senior Vice President, Pharmaceutical Development and Manufacturing Operations for Nektar Therapeutics since August 2010. In this position, Dr. Hora is responsible for all process, product, analytical and device development as well as manufacturing activities for Nektar. From 2006 to 2010, Dr. Hora served as Vice President in Product and Quality Operations at Facet Biotech (now Abbvie) and PDL Biopharma. From 1986 to 2006, Dr. Hora held positions of increasing responsibility with Chiron Corporation (now Novartis) serving most recently as Vice President of Process and Product Development. Dr. Hora served as a key member of various teams that successfully registered eight drugs or vaccines in the U.S. and Europe during his >25-year in the biopharmaceutical industry. Dr. Hora completed his Ph.D. in Bioengineering from the Indian Institute of Technology, Delhi, India, and was a Fulbright Scholar at the University of Washington, Seattle before joining the industry. Dr. Hora holds 21 US patents and has published and presented extensively in scientific journals and symposia.

Zosano Pharma: Better Therapeutics Through Innovative Delivery

A novel technology, efficient and user-friendly transdermal drug delivery patch with significant therapeutic effects.



Mr. Zander Strange

VP, Strategy and
Corporate
Development,
Zosano Pharma

Zosano Pharma is a clinical stage biopharmaceutical company specializing in transdermal drug delivery. Our technology consists of an applicator and microneedle patch, with key differentiating features being rapid drug delivery (resulting in fast onset), stable formulation at room temperature, and a simple and intuitive easy-to-use device. Zosano has shown technical feasibility with 30 compounds coated onto our microneedle technology. We select products for commercial development that have high price points in large attractive markets. Our lead product candidates include Weekly and Daily ZP-PTH for the treatment of severe osteoporosis and ZP-Glucagon for the treatment of severe hypoglycemia. For Weekly ZP-PTH, our Phase 1 data demonstrated pulsatile delivery with all of our patch doses (a critical factor for all anabolics). In Phase 2 for Daily ZP-PTH, we observed higher hip BMD (bone mineral density) and comparable spine BMD gains versus the currently marketed product – Forteo®. ZP-Glucagon data demonstrated a shorter T-max and high bioavailability with all of our patches versus a glucagon injection, which are important features for the treatment of severe hypoglycemia (fast onset critical in emergency setting with unresponsive patient).

Speaker Profile

Zander Strange is the Vice President, Strategy and Corporate Development at Zosano Pharma, a microneedle drug delivery company in Fremont, CA. Zander has extensive experience in strategic planning, business development, capital raising and financial reporting. He has executed a number of transactions at Zosano, including a \$60 million licensing agreement with Novo Nordisk and a venture debt financing with Hercules Technology Growth Capital. Prior to Zosano, Zander was Manager of Business Development and Finance at Predictive Biosciences, where he worked on financial reporting and capital raising, and at Leerink Partners, a healthcare-focused investment bank, where he executed a number of financing and M&A transactions, including private placements, IPOs, Follow-Ons and buy- and sell-side acquisitions. Zander holds a BA from the University of Virginia.

*RNAscope®
technology, the first
automated multiplex
chromogenic and
fluorescent in situ
hybridization
platform capable of
detecting and
quantifying RNA
biomarkers in situ at
single-molecule
sensitivity.*



**Dr. Christopher
Bunker**

**VP of Business
Development,
Advanced Cell
Diagnostics, Inc.**

Advanced Cell Diagnostics, Inc. – Developing breakthrough technologies for precision molecular diagnostics to enable more effective cancer treatment with targeted therapeutics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. RNAscope assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD's industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com.

Speaker Profile

Dr. Christopher Bunker is the Vice President of Business Development at Advanced Cell Diagnostics (ACD) in Hayward, California. He joined ACD in 2010 to lead market and business development of its proprietary RNAscope® biomarker platform, which is now employed in translational research and clinical development with every major U.S. and European biopharma company. Prior to joining ACD, Dr. Bunker obtained his MBA in the executive program at Boston University while Senior Director of Business Development at Cell Signaling Technology (CST). He was with CST for ten years first leading biopharma market development and then its antibody and proteomics business development. Dr. Bunker was a senior scientist in functional genomics at Genome Therapeutics Corporation. His doctoral research was in the laboratory of Dr. Robert E. Kingston at Harvard University and Massachusetts General Hospital, and he was a Leukemia Society of America postdoctoral fellow in the laboratory of Patrick O'Farrell at the University of California, San Francisco.

Mobile Health: Rising Tide in Healthcare Industry

*By the end of 2017,
the total mHealth
market revenue will
have grown by 61%
(CAGR) to reach
US\$26 billion.*

Mobile Health (mHealth) is an attractive solution that leverages the ubiquity of mobile devices to address the prevalent problem of access to healthcare and rising costs. The growing rate of mobile adoption, coupled with the pressing challenge of finding alternative ways to reduce healthcare costs, provides a ripe opportunity to expand the mHealth market. By the end of 2017, the total mHealth market revenue will have grown by 61% (CAGR) to reach \$26 billion. Besides, 500 million Smartphone users will use health apps by 2015. Mobile Health will impact not only the healthcare industry, but also everyone's daily life.

Numerous players have joined in the battlefield, including big IT giants, wearable device manufacturers, insurance companies, and healthcare service providers. It is not just a product-sale business; it is a competition of providing total solution for healthcare. Apple's Health Kit, Google Fit, and Samsung's S5 S Health enable you to track your health condition with your mobile device. Beside big companies, there are plenty of startups attracting VCs' eyes. 143 companies have successfully raised \$2.3 billion in the first half of 2014, which surpassed 2013's total investment in mHealth.

In this speech, Dr. Chao will share his experience in developing tele-medicine and mHealth from a technological point of view, and observation in worldwide mHealth development trend. He will also discuss the future prospect of this rising tide.



Dr. Gabriel Chao

STB Scholar
RD Director, iXensor

Speaker Profile

Gabriel, Pin-tsun Chao (趙品尊) was born in Taichung, Taiwan. He received a B.S. degree in electrical engineering from National Taiwan University in 2000, and a Ph.D. in electrical engineering from National Taiwan University in 2006.

Dr. Chao has 10+ years experience with innovative medical device development. His projects were included Chinese traditional medicine modernization (pulse diagnosis device), non-invasive glucose measurement, and microcirculation analyzing system. After finishing military service, he worked as an associate researcher in STB program. He was responsible for bridging Silicon Valley and Taiwan Medtech community, and introduced the process of innovative medical device development to Taiwan. With his experience in medical device regulation, he was also a committee member of Taiwan medical device standard (invited by BSMI in MOEA), and adjunct assistant professor in NTUST.

With his expertise in regulation and mobile device, he joined iXensor, a mobile health device company, as RD director in 2013. His duties included product development, patent, regulation and technology cooperation. He was selected a STB scholar in 2013 and started at Stanford in July 2014.

Percans is a medical service company providing tailored solutions for each individual cancer patient with our I-Graft technology platform.



Dr. Yiyou Chen

CEO
Percans Oncology

The Percans Story

Among major disease categories, cancer ranks the lowest in terms of treatment efficacy, due to the enormous heterogeneity in gene mutation and drug sensitivity. Percans explores the highly predictive nature of patient autologous xenograft (*I-Graft*TM) which allows clinicians to test a variety of drugs and drug combinations in search of the best treatment regimen for the donor patient, even in the absence of known target mutations. It can be further expanded to drugs which are still under clinical development, and serve as a tool to prioritize patient enrollment in various clinical trials.

Speaker Profile

Dr. Yiyou Chen is the CEO and Co-founder of New Horizon Bioscience Inc., a biopharmaceutical company developing novel cancer therapeutics and diagnostics. Dr. Chen also serves as the Chairman of Percans Oncology, a clinical oncology service company providing individualized and highly predictive cancer drug sensitivity assays to support clinical decision making.

Prior to founding New Horizon, Dr. Chen was the Chief Scientific Officer and Co-founder of Crown Bioscience Inc., a leading biotech company providing services to global life science companies specializing in oncology and metabolic disease. The company leverages its strength in drug discovery and translational medicine to help our partners develop innovative therapeutics with clinical relevancy. He was widely recognized as a leader in translational oncology research, and accredited for the establishment of the industry leading HuPrime® technology platform. Besides his role in leading the scientific research, Dr. Chen was also responsible for CrownBio's global sales, marketing, and strategic alliance effort. Under his leadership, CrownBio has established drug discovery partnerships with nearly all of the major global pharmaceutical companies.

Before CrownBio, Dr. Chen was the Chief Scientific Officer and Co-founder of Starvax Inc., a bio-pharmaceutical company based in Beijing, focusing on the development of recombinant vaccines for infectious disease and cancer. Prior to Starvax, he was a senior scientist and project leader at Genencor International, a global biotechnology company with over \$1 billion dollars in annual revenue.

Dr. Chen is currently an advisor for Crown Bioscience Inc., and a board member of San Diego based Med Data Quest. Dr. Chen was one of the founding members of the BayHelix Group, a global leadership group for Chinese biopharmaceutical executives. In the last 10 years, he has given multiple invited speeches on both Chinese and international science and business forums. Dr. Chen obtained his BS in Biochemistry from Peking University, and his Ph.D. in Experimental Pathology from University of Utah School of Medicine.

SPONSORS



ORGANIZATION

Mission

The Chinese Bioscience Association (CBA) is a non-profit organization founded in the San Francisco Bay area in 1997. Its mission is to promote education, networking and community building for life science professionals.

LOCAL PARTICIPATION

Since its foundation, CBA has held hundreds of scientific conferences, seminars and workshops focusing on emerging trends and cutting-edge technologies in the biotech/pharmaceutical industry. CBA currently has hundreds of active members and supporters ranging from CEOs, founders, business executives, professors, directors, managers, scientists, students and postdocs.

GLOBAL CONNECTIONS

As a bi-lingual organization, CBA plays a key role bridging the industry and cultural gaps between US and Asia, and has strong ties to Taiwan, Mainland China, Hong Kong and Singapore. The annual conferences and summer picnic events are especially popular with members, friends and families. CBA is a volunteer organization supported generously by its sponsors and members.

2014 Board and Advisors

President: Michelle Chen

Vice President: Patty Kiang

Secretary: Angie Wu, Mark Chen

Treasurer: Katherine Wang

Membership: Kai Zheng

Press Relationship: Huifang Li

E-communication: Pengguang Wu

Publications: Cindy Liu

Sponsorship: Jing Folsom

Alliances: Patrick Yang

Scholarship: Caesar Ho

Newsletter: Mark Chen

Taiwan Liaisons: Frank Lin, Andrew Teng

Advisors: Lin Sun-Hoffman, Sydney Chen, Rong-Hwa Lin, Kelley Liu, Guoliang Yu

Conference Advisors: Son Kuan, Ta-Kai Li, Julie Yang, Cheng-Chi Chao

Special thanks to: Emily Yan, Yi-Fei Lee, Jennifer Shih, Shih-Chen Chang, Chen-Ming Chang, Jian Cao, Shirley Zhang, Xiaolong Yang

2014 Events and Activities

February 22: Welcome Lunch for new Board and advisors

February 26: The 7th US-Taiwan Biomedical Engineering Forum Discussion (Co-organized with TECO)

May 6: Big Data Workshop (Co-organized with BayHelix; Sponsored by Morrison & Foerster)

May 28: Job Search and Interview Workshop (Co-organized with CABS at Stanford University)

June 19: Investing Across Borders (Co-organized with BayBio; Sponsored by Onyx Pharmaceuticals)

August 2: WEZ Science Park Visit Silicon Valley Reception (Sponsored by Fenwick & West)

August 16: CBA Annual Summer Picnic at Mitchell Park, Palo Alto

September 17: UTBEE Biomedical Device Forum (Co-organized with CASPA)

October 4: New Waves in the Biotech Industry (17th CBA Annual Conference)

October 19: 2014 HiRecruit Job Fair (Co-organized with Taiwan Trade Center, San Francisco)

KEY EVENT

Big Data Challenges Workshop

Date/Time: Tuesday, May 6, 2014, 5:30 pm – 8:30 pm
Venue: Morrison & Foerster, Palo Alto, CA
Event Chair: Dr. Lin Sun-Hoffman
Moderator: Dr. Michelle Chen

High throughput “OMICS” technologies including next generation sequencing (NGS) have become essential tools for a wide range of biotech research and enable the study of genomic changes with high resolution. However, the challenge of managing and analyzing the Big Data generated from NGS are far from having a satisfactory solution. The goal of this workshop is to facilitate discussions with the experts how to address these challenges.

Speakers:

- Dr. Howard Ho, Research Manager and Research Staff Member, IBM Almaden Research Center
- Dr. Licen Xu, Senior Director, Life Science Group, ThermoFisher Scientific
- Dr. Bruce Ling, Principal Investigator, Stanford University



KEY EVENT

Job Search and Interview Workshop

Date/Time: Wednesday, May 28, 2014, 5:30 pm – 8:30 pm

Venue: Stanford University, Stanford, CA

Event Chair: Dr. Michelle Chen

Moderators: Dr. Kai Zheng and Dr. Sean Wu

Job search could be a long and stressful process and a job interview is one of the most drawn-out and intimidating ways of making first impression. The way you behave in your first interview will be highly important in getting your desired job. However, it's also your opportunity to get on an employer's good side, which can give you a distinct edge over even those applicants whose credentials are better than yours. In this special event, experienced recruiters and industry elites will share with their valuable advice and experience to help you succeed in your job search and interview, and start your career in biopharmaceutical industry.

Speakers:

- Dr. Melisa S. Medrano, Staffing Consultant, Gilead Sciences
- Ms. Katherine Yagel, Director of Professional Services for Lee Hecht Harrison
- Mr. Howard Simon, J.D., Chief Operating Officer and General Counsel, DNA2.0
- Dr. Leping Li, Vice President of Chemistry at Presidio Pharmaceuticals
- Mr. Don Lim, Senior Recruiter, Yahoo and previously at Onyx



KEY EVENT

Investing Across Borders: Asian Biotech Investors Panel and Reception

Date/Time: Tuesday, June 19, 2014, 5:00 pm – 8:00 pm
Venue: Onyx Pharmaceuticals, South San Francisco, CA
Event Chair: Dr. Michelle Chen

With the growing appetite for life science investment in Asia and from Asia, there comes opportunity. The Investing Across Borders: Asian Biotech Investors Panel & Reception will provide the unique opportunity for life science entrepreneurs to meet and have dialogue with this distinguished group of Asian investors. The panel will share their perspectives on:

- What's 'hot' in life sciences and investment outlook
- The evolving investment landscape for biotech
- Finding value and managing risk when identify promising biotech investment opportunities
- The changing role of traditional venture financing and new forms of collaboration
- Funding early stage biotech start ups: What role should investors, pharma and government play?

Investor Panel:

- Dr. Graeme Martin, President and CEO, Takeda Ventures
- Dr. Wenbao (Wayne) Li, General Project Manager, Morningside Group
- Dr. Sofie Qiao, Managing Director, WuXi Venture
- Dr. Min Cui, Managing Director, Decheng Capital



KEY EVENT

Annual Summer Picnic

Date/Time: Saturday, August 16, 2014, 11:00 pm – 2:00 pm
Venue: Mitchell Park, Palo Alto, CA
Coordinator: Jing Folsom



Monthly Newsletters



BIOSCIENCE COMMUNITY

CBA Membership

Why join?

- Networking for success
- Attend professional meetings, seminars, and workshops
- Connect with other professionals and share technical interests
- Keep skills and knowledge current and relevant
- Create new partnerships

CBA Volunteering

Why participate?


- Have a positive impact on community
- Share passion, talents and expertise with others
- Hone leadership and management skills
- Develop interpersonal skills
- Balance lifestyle
- Strengthen personal/professional vision and commitment

CBA Member Benefits

- Free or discounted admission to seminars and workshops
- Free admission to Annual Summer Picnic
- Free or discounted admission to Annual Conference
- Members' children can apply for the Youth Scholarship Program (New)
- Online career resources including job posting
- Eligibility to vote / become a board member

Member Profile

- Members/participants in the survey at the CBA Annual Conference (N=124)




CBA HISTORY

2009-2013 Officers

Year	President	Vice President	Secretary	Treasurer
2013	Lin Sun-Hoffman	Shih-Chen Chang	Angie Wu	Katherine Wang
2012	Peiwen Yu	Son Kuan/Andrew Teng	Shwu-Hwa Lin	Katherine Wang
2011	Patty Kiang	N/A	Cindy Liu	Katherine Wang
2010	Sydney Chen	Patty Kiang/Yong-Liang Zhu	Ta-Kai Li	Katherine Wang
2009	Stella Chang	Sydney Chen	Ta-Kai Li	Katherine Wang

2009-2013 Publications



1998-2008 Officers

Year	President	Vice President
2008	Lichun Huang	N/A
2007	Kelley Liu/ Fong-Yih Bih	Cheng-Chi Chao
2006	Betty Chang	N/A
2005	Joshua Chang	Fong-Yih Bih
2004	Jer-Kang Chen	N/A
2003	Effie Lin	Jer-Kang Chen
2002	Jin-Chen Yu	Effie Lin
2001	Maureen Wang/ Jin-Chen Yu	Effie Lin
2000	Maureen Wang	Jin-Chen Yu
1999	James Fann	Maureen Wang
1998	Shian Jiun Shih	James Fann

With few connections outside of our individual workplaces, many of our original members sought to socialize with other Chinese professionals in the bio-science field. Eventually, our casual socials turned increasing academic as our shared interests in bio-science compelled us to seek out more established individuals in the field to share their experiences and knowledge. With a desire to learn, therefore, our humble group of Bio-scientists formed the beginning of CBA. Looking back now, with our fantastic annual conference and many members, it is amazing to see how much our organization has grown. As a past president, I am truly grateful that so many of you still share our passion for kinship and Bioscience. I wish you all the best, and hope that you all enjoy another successful annual conference.

James Fann, Ph.D.

1999 President's Message

The Chinese Bioscience Association started in late 90's from a scatter of individual Chinese Bio-scientists working at San Francisco Bay Area.

COLLEGE CONNECTION

College Application:

FAQ for College Admissions: www.petersons.com/college-search/college-questions.aspx
Webpages of All U.S. Universities, by State: www.utexas.edu/world/univ/state/
Free Application for Federal Student Aid (FAFSA), including grants, scholarships, work-study and loans: www.fafsa.ed.gov
Asian & Pacific Islander American Scholarship Fund: www.apiasf.org
Transfer Information System of Course Credits Earned at California College or University: www.assist.org
University of California Education Abroad Program: eap.ucop.edu
Study Abroad Programs in Asia: www.gooverseas.com/study-abroad/asia

Test Preparation for College:

SAT Biology Test Practice: sat.collegeboard.org/practice/sat-subject-test-preparation/biology-em
ACT Science Sample Test: www.act.org/caap/sampletest/pdf/Science.pdf
AP Biology Exam Practice: <https://apstudent.collegeboard.org/apcourse/ap-biology/exam-practice>

Professional Programs:

Medical School Admission Requirements: <https://www.aamc.org/students/applying/requirements/>
Pharmacy School Admission Requirements: www.aacp.org/resources/student/pharmacyforyou/admissions/pages/psar.aspx
Veterinary School Course Prerequisites: www.aavmc.org/data/files/vmcas/prereqchart.pdf
Dental Schools and Programs: www.ada.org/en/education-careers/dental-schools-and-programs

Graduate Programs:

Top Graduate Programs in Biological Sciences: grad-schools.usnews.rankingsandreviews.com/best-graduate-schools/top-science-schools/biological-sciences-rankings
Graduate School Discussion and Results: www.thegradcafe.com
Contacting Potential Advisors for Graduate School Research: www.usnews.com/education/blogs/graduate-school-road-map/2012/09/28/how-to-contact-professors-as-a-grad-school-applicant

Preparation for Graduate School:

GRE General Test Prep: www.ets.org/gre/revised_general/prepare
GRE Subject Test Practice for Biochemistry, Cell and Molecular Biology: www.ets.org/s/gre/pdf/practice_book_biochem.pdf
GRE Subject Test Practice for Biology: www.ets.org/s/gre/pdf/practice_book_biology.pdf
Graduate School Application Timeline: www.idealists.org/info/GradEducation/Resources/Preparing/Timeline
Tips for Writing Your Statement of Purpose: www.training.nih.gov/_assets/slides_7-17-12
Requesting a Letter of Recommendation from a Professor or Advisor: gradschool.about.com/od/askingforletters/a/askletter.htm?rd=1
Preparing for a Graduate School Interview: <http://gradschool.about.com/od/interviews/a/intquest.htm>

Jobs, Careers and Salaries:

Job Search and Career Info for College Student and Recent Graduate: www.collegegrad.com, www.studentjobs.gov, www.coolworks.com, www.careervoyages.gov
Careers in Biotechnology. A Counselor's Guide to the Best Jobs in the U.S.: www.bio-link.org/home/sites/files/careersinbiotech20088e-j.pdf
Average Salary Ranges for Biotech Jobs: www1.salary.com/Biotechnology-Salaries-6.html#S
Average Salary Ranges for Pharmaceuticals Jobs: www1.salary.com/Pharmaceuticals-salaries.html

Contributor


Angie Wu graduated from UC Davis in 2012. During her undergraduate studies she conducted research on topics as varied as heart disease, rheumatoid arthritis, and marine ecosystem conservation. She is currently a graduate student in Biostatistics at Duke University.



About AbGenomics International

AbGenomics International incorporated in Delaware US, is a biopharmaceutical company integrated globally and virtually to develop targeted therapeutics for the treatment of cancer and immune related inflammatory diseases. AbGenomics has full capacities from managing research discovery, preclinical and clinical development, as well as strategic planning to commercialization of its therapeutics through collaboration with alliance partners. Numbers of highly differentiated and best-in-class drug candidates have been developed in our company pipelines.

Our pipelines



Partnerships and Strategic Alliances

AbGenomics believes working collaboratively is a key to success in maintaining competitiveness in the Biotech industry. AbGenomics welcomes every collaboration opportunity with academic institutions, biotech and pharmaceutical companies worldwide in new drug discovery, development, and marketing.

Career Opportunity

We are constantly looking for high-energy, talented people who want to make a meaningful difference for our company especially Controller/ VP of Finance and Project Manager. Please see our website for the details.

Contact Us

For more information about our products, services, partnership, and collaboration and job opportunity, please contact: **AbGenomics International, Inc.**

<http://www.abgenomics.com/>

e-mail: abg@abgenomics.com

Custom Peptide Synthesis & cGMP Peptide Production

Fully Licensed

Our cGMP peptide production facility is FDA Licensed and maintains a Drug Manufacturing License issued by the State of California, Department of Public Health Services, Food and Drug Branch. C S Bio is fully licensed and equipped to produce clinical grade peptides.

Dedicated cGMP Facility


Our approach to cGMP Manufacturing includes dedicating a production line and team of chemists to each project. This is to assure confidentiality, avoid cross-contamination and to simplify reporting to clients and regulatory agencies.

Complete cGMP Documentation

We supply our clients with all cGMP related documentation including Batch Process Records, Raw Material CoA's and final QC Data. We feel it is imperative to work closely with our clients to maintain quality and to assure compliance. We welcome new and existing clients for inspection and audits.



CS Bio Co.
People Who Know Peptides



Peptide Synthesizers



R&D Scale Models

CS336X and CS136XT

Reaction Vessel Sizes from 10 mL to 250 mL

Industrial Scale Models

CS536XT and CS936S, CS936 & CS936X
Reaction Vessel Sizes from 50 mL to 1000 L



CS Bio Co.

20 Kelly Court, Menlo Park, CA 94025 USA Telephone: (650) 322-1111 • Fax: (650) 322-2278

Web: www.csbio.com • E-mail: peptides@csbio.com

BIOFIBROSCORE[®]

A NON-INVASIVE LIVER FIBROSIS PLATFORM

Biopsy Alternative

- Blood sampling method
- 3 biomarkers and an algorithm to generate results in 4 different stages (correlated from biopsy)
- Validated with 500+ samples

Announcing Liver20[™] Service

- Providing a 20-test liver panel testing from inflammation, fibrosis, to liver cancer (HCC)
- Offering you a personalized report to understand your liver better



A No.6, Innovation First Road, Hsinchu Science Park, Taiwan, R.O.C.

E sales.group@gbc.com.tw

T +886 3 577 9221

www.gbc.com.tw

Sunny Pharmtech

Sunny Pharmtech, Inc. is a newly established specialty pharmaceutical company merged from two companies with 4 and 10 years experiences, respectively. We develop 505B2 new drugs as well as generic products. Our drug product development is backed up with API capability. Through our CMOs for now we aim to bring our drug products to US and worldwide markets. We are planning our own production site for expanding product portfolio.

Our product categories include:

- (1) 505B2 products for supportive cancer care (e.g. anti-mucositis).
- (2) Oral generics in foam, tablet, semi-solid, suspension and liquid forms; both IR and MR
- (3) Injections and Injectables for oncology and non-oncology indications.
- (4) Otic and ophthalmic products.
- (5) Active Pharmaceutical Ingredients.

We have the following openings at our Taipei and Taoyuan operations. Please send your resume to yonlian.wu@sunnypharmtech.com.

- (1) Director, API Process Development and Scale-up
- (2) Director, Oral Formulation Development
- (3) Director, Injectable Development
- (4) Director, Quality Control
- (5) Director, Quality Assurance and Regulatory Affairs
- (6) Director, Business Development
- (7) Engineers and/or Researchers for development of drug substances and drug products

祥翊製藥股份有限公司 Sunny Pharmtech Inc.

台北研發處 Taipei office:
22203 新北市深坑區北深路3段155巷27號10樓
Tel: 886-2-26649600 Fax: 886-2-26643310
10F, No. 27 Lane 155, Section 3, Beishen Road,
Shenkeng District, New Taipei City, Taiwan 22203

桃園研發處 Taoyuan office :
32062 桃園縣中壢市吉林路27-2號6樓
Tel: 886-3-4633930 Fax: 886-3-4633011
6F, No. 27-2, Jilin Rd., Zhongli City, Taoyuan County,
Taiwan 32062

Plug in to the best connected city in Asia



Hong Kong's strategic location and world-class infrastructure make it an ideal business hub in Asia. Its legal framework, simple tax regime, availability of finance sources, top-notch R & D facilities and stringent intellectual property protection make it the perfect place for technology businesses.

Invest Hong Kong has the expertise to help you set up smoothly in our city. Our services are free, confidential and tailored to your needs.

Get in touch at investhk.gov.hk

InvestHK

The Government of the Hong Kong
Special Administrative Region

Where Business Goes to Grow

San Francisco office: Lawrence Tang
Tel: (1) 415 835 9318
Email: lawrence_tang@hketosf.gov.hk

Head office:
Tel: (852) 3107 1000
Email: enq@investhk.gov.hk

New York office: D. Kelly Jones
Tel: (1) 212 752 3320 Ext.213
Email: kelly_jones@hketony.gov.hk

#investhk



Follow us on 



OUTWIT. OUTSOURCE. OUTSHINE.

With the addition of a world class parenteral manufacturing facility, Irvine's experts are now even better positioned to guide you through and expedite your time to market.

- 25 Years providing pharmaceutical/biopharmaceutical analytical CMC support from preclinical to post-market
- Formulation development
- Manufacturing of small volume parenterals and lyophilizates

Your single source for pharmaceutical development.



OUTWIT. OUTSOURCE. OUTSHINE.

Visit www.irvinepharma.com or call 877.445.6554.



工業技術研究院

Industrial Technology
Research Institute

www.itri.org.tw



Innovating a Better Future

Innovation, Integrity, Sharing

創新 誠信 分享

Advanced
Manufacturing
and Systems


Biomedical
Technology

Energy and
Environmental

Information and
Communications
Technologies

Electronics and
Optoelectronics

Nanotechnology,
Material and Chemical



The Wall Street Journal **Gold**

Technology
Innovation Awards



Ways to Work with ITRI:

- Technology transfer or exchange
- IP pooling and/or auction services

- ITRI provides R&D contract services
- Joint development and IPR sharing
- Facilities sharing and incubation
(ITRI HQ's Open Lab and Silicon Valley)

Contact: information@itri.com

ITRI International Inc. ▶ 2870 Zanker Rd. Suite 140, San Jose, CA 95134; +1-408-428-9988



WWW.FORMEXLLC.COM



Formex
Formulation Experts

HOT-MELT EXTRUSION
 SPRAY-DRIED DISPERSIONS
 CYTOTOXIC AND HIGH POTENT CAPABILITIES
 CGMP MANUFACTURING
 BIOAVAILABILITY ENHANCEMENT
 PRE-FORMULATION



Your personal financial goals deserve a *personal approach*

Putting the needs of clients first is the approach I believe in. I'll work with you to find the right financial solutions to help you plan for your unique goals. And together, we'll track your progress over time, adjusting your plan along the way to help get you where you want to go.



The C & G Group

A financial advisory practice of
Ameriprise Financial Services, Inc.

255 Shoreline Drive, Ste 400
Redwood Shores, CA 94065

650.226.2106

Andrew Gotianse, AAMS®, CMFC®

Accredited Portfolio Management AdvisorSM
Financial Advisor • Associate Vice President
andrew.gotianse@ampf.com
ameripriseadvisors.com/the-c-g-group
CA Insurance #OD97394

Dong Choi, CFP®

Financial Advisor • Vice President
dong.choi@ampf.com
ameripriseadvisors.com/the-c-g-group
CA Insurance #OE16074




Ameriprise Financial Services, Inc. Member FINRA and SIPC.

© 2013 Ameriprise Financial, Inc. All rights reserved.

WELCOME YOUR PARTICIPATION

HSINCHU SCIENCE PARK



We welcome high-tech elite like you to explore promising careers and to pioneer the world together.



Hsinchu Science Park Bureau, Ministry of Science and Technology
2 Hsin Ann Road, Hsinchu, Taiwan 300
Tel: 886-3-5773311 Fax: 886-3-5776222
[Http://www.sipa.gov.tw](http://www.sipa.gov.tw)

廣告

When I worked in biopharmaceuticals (first with Roche/Genentech, then with De Young & Hayden, LLC), I was an active member of the CBA. I found it to be a very helpful and interesting organization filled with extremely bright, highly professional, and friendly scientists.

Now that I have changed professions, I want to give something back, so I am happy to be a “corporate” sponsor.

Every time a CBA member buys or sells property through me (or makes a referral that leads to a transaction), I will make a donation back to CBA. In addition, I will also discount my listing commission for home sellers and provide a free Home Warrantee policy for home buyers for any CBA members and their referrals.

bradleyhayden@kw.com

650 218-3379

www.bradleyhayden.com

Get free real estate information at
www.BayAreaRealtyInfo.com



紐約人壽
傳家之保®

Agent, New York Life Insurance Company

Julia Hsiao

J.D., LL.M.

Financial Advisor*

CA Ins. License #0B43293



- ◆ Council Agent in New York Life Since 1998
- ◆ Qualifying & Life member, MDRT Court of the Table**
- ◆ Member, Santa Clara Estate Planning Council since 1998
- ◆ Financial Adviser, Eagle Strategies LLC, A registered investment adviser

(408) 863-0306 (B)
(408) 252-1005 (Fax)
2 0480 Pacifica Dr., #G
Cupertino, CA 95014
julia@calljulia.com
www.calljulia.com

*Offering investment advisory services through Eagle Strategies LLC, A Registered Investment Adviser. Registered Representative for NYLIFE Securities LLC (Member FINRA/SIPC), A Licensed Insurance Agency. Eagle Strategies LLC and NYLIFE Securities LLC are subsidiaries of New York Life Insurance Company. Neither New York Life Insurance Company, nor its agents, provide tax, legal, or accounting advice. Please consult your own tax, legal, or accounting professionals before making any decisions. **MDRT, The Premier Organization of Financial Professionals, is recognized globally as the standard of excellence in life insurance sales performance in the insurance and financial services industry.
SMRU# 532501

Exhibitors:

Advanced Cell Diagnostics
Alava Biopharm Partners
Ameriprise Financial Services
Alzheimer Association
Applied StemCell
BizGenius
Catalent
Climax
CPC Scientific
Crown Bioscience
Ding Ding TV
Formex
GenScript
InvestHK
Irvine Pharmaceuticals
JHL Biotech
Pure Biologics
Shanghai Medicilon
Thermo Fisher

Advertisers:

AbGenomics International
Ameriprise Financial Services
Bradley Hayden
CS Bio
Formex
General Biologicals
Gilead
Hsinchu Science Park
InvestHK
Irvine Pharmaceuticals
ITRI
Julia Hsiao
ScinoPharm
Sunny Pharmtech
TECO San Francisco

Science & Technology Division

Taipei Economic & Cultural Office in San Francisco

駐舊金山台北經濟文化辦事處科技組

5201 Great America Parkway, Suite 200

Santa Clara, CA 95054

Tel: (408) 986-8686

Fax: (408) 986-8066

E-mail: sdsf@sciencesf.org

<http://sf.nsc.gov.tw>



We are here to serve you..

加拿大科技組

<http://canada.nsc.gov.tw>



舊金山科技組

<http://sf.nsc.gov.tw>



- ▶ 加強台美加科技交流合作
- ▶ 擴大海外人才延攬之平台
- ▶ 協助全台科學園區之招商
- ▶ 支持駐地科技社團之活動
- ▶ 媒合台灣與美加技術資金
- ▶ 引進科技新知及技術移轉

華盛頓科技組

<http://dc.nsc.gov.tw>



洛杉磯科技組

<http://la.nsc.gov.tw>



休士頓科技組

<http://houston.nsc.gov.tw>





Advancing Therapeutics, Improving Lives.

For more than 25 years, Gilead has been committed to developing medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, hepatitis, serious respiratory and cardiovascular conditions, cancer and inflammation.

Every day we strive to transform and simplify care for people with life-threatening illnesses.

GILEAD IS HIRING FOR A VARIETY OF ROLES IN NORTH AMERICA, EUROPE AND ASIA-PACIFIC. LEARN MORE AND APPLY AT WWW.GILEAD.COM/CAREERS.



For more information, please visit www.gilead.com.
© 2013 Gilead Sciences, Inc.